Scientists have completed the first-ever genetic mapping of tumor cells from Taiwanese with breast cancer in a potential breakthrough for treatment and prevention of the disease. National Cancer ...

An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Prenatal gene therapy via mRNA LNPs fixes faulty genes in fetal brain cells in animal model of neurodevelopmental syndrome.

New research underscores the role of the immune system in depression, linking inflammation to poor response to standard ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

The 2024-2025 COVID-19 vaccines are available, and the CDC recommends that adults over 65 and immunocompromised people get ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

The partners will use Pangea's ENLIGHT-DP platform to analyze data from two clinical studies at OHSU and improve understanding to tumor resistance and response.

A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent patients aged 5 years and older.

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $52.8 which represents a decrease of $-0.59 or -1.11% from the prior close of $53.39. The stock opened at $53.39 and touched a ...